# BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

> **NCT01314105** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 19 (actual)

## Conditions studied

- Ovarian Neoplasms
- Peritoneal Neoplasms

## Interventions

- **DRUG:** BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- **DRUG:** BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- **DRUG:** BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min

## Key facts

- **NCT ID:** NCT01314105
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-15
- **Primary completion:** 2013-07-29
- **Final completion:** 2016-04-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314105, "BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01314105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*